No inherited causative genetic variants or germline inheritance patterns are documented for acromegaly in the current packet. The disease is classified as an acquired disorder linked to excessive GH production. No OMIM identifier is on record in this packet.

Diagnostic criteria and methods for acromegaly are not certified in the current packet. The disease definition characterizes the condition as an acquired disorder related to excessive GH production with somatic and systemic manifestations.

Multiple FDA-approved pharmacologic agents are documented for acromegaly with active market status. Somatostatin analogs include octreotide acetate in formulations approved across multiple decades: Sandostatin (approved 1988), Sandostatin LAR Depot (approved 1998), and Bynfezia Pen (approved 2024). Oral octreotide (Mycapssa) was approved in 2020. Pasireotide, a multireceptor somatostatin analog, is approved as Signifor (2012) and Signifor LAR (2014). Pegvisomant (Somavert), a GH receptor antagonist, has been FDA-approved since 2003. Paltusotine (Palsonify), an oral nonpeptide somatostatin receptor agonist, received FDA approval in September 2025, representing the most recently approved agent in the packet. Multiple additional agents carry orphan drug designation status for acromegaly.

Prognosis data and natural history metrics for acromegaly are not certified in the current packet beyond the characterization of progressive somatic disfigurement in the disease definition.

Acromegaly has 265 classified publications documented, with review and meta-analysis articles as the dominant research type (96 of 265), alongside biomarker and recent trial publications. Active acromegaly-specific clinical trials include a Phase 3 study of Debio 4126 in participants previously treated with somatostatin analogs (NCT06930625, Debiopharm, recruiting), a Phase 2 study of ALXN2420 combined with somatostatin analogs (NCT07037420, Alexion, recruiting), a Phase 2 study of MAR002 (NCT07641179), and a Phase 3 octreotide long-acting injection study (NCT07623824).